Jordan E Pinsker1, Lars Müller2, Alexandra Constantin3, Scott Leas4, Michelle Manning5, Molly McElwee Malloy6, Harsimran Singh7, Steph Habif8. 1. Sansum Diabetes Research Institute, 2219 Bath St., Santa Barbara, California, United States, 93105; jpinsker@sansum.org. 2. UC San Diego, 8784, Design Lab, La Jolla, California, United States; lamueller@ucsd.edu. 3. Tandem Diabetes Care, Data Science, San Diego, California, United States; alconstantin@tandemdiabetes.com. 4. Tandem Diabetes Care, Data Science, San Diego, California, United States; SLeas@tandemdiabetes.com. 5. Tandem Diabetes Care, Behavioral Sciences, San Diego, California, United States; MManning@tandemdiabetes.com. 6. Tandem Diabetes Care, Behavioral Sciences, San Diego, California, United States; mmcelweemalloy@tandemdiabetes.com. 7. Tandem Diabetes Care, Behavioral Sciences, San Diego, California, United States; HSingh@tandemdiabetes.com. 8. Tandem Diabetes Care, Behavioral Sciences, San Diego, California, United States; SHabif@tandemdiabetes.com.
Abstract
BACKGROUND: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. METHODS: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). PROs and glycemic outcomes were reviewed at each timepoint. RESULTS: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. TIR was 78.2% (70.2-85.1%) at T1 and 79.2% (70.3-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the CGM as being valuable features of the system. CONCLUSIONS: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended time-in-range glycemic outcomes in people with T1D.
BACKGROUND: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. METHODS: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). PROs and glycemic outcomes were reviewed at each timepoint. RESULTS: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. TIR was 78.2% (70.2-85.1%) at T1 and 79.2% (70.3-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the CGM as being valuable features of the system. CONCLUSIONS: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended time-in-range glycemic outcomes in people with T1D.
Authors: Sue A Brown; Roy W Beck; Dan Raghinaru; Bruce A Buckingham; Lori M Laffel; R Paul Wadwa; Yogish C Kudva; Carol J Levy; Jordan E Pinsker; Eyal Dassau; Francis J Doyle; Louise Ambler-Osborn; Stacey M Anderson; Mei Mei Church; Laya Ekhlaspour; Gregory P Forlenza; Camilla Levister; Vinaya Simha; Marc D Breton; Craig Kollman; John W Lum; Boris P Kovatchev Journal: Diabetes Care Date: 2020-05-29 Impact factor: 19.112
Authors: Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg Journal: Diabetes Technol Ther Date: 2019-01-18 Impact factor: 6.118
Authors: T R S Hajos; F Pouwer; S E Skovlund; B L Den Oudsten; P H L M Geelhoed-Duijvestijn; C J Tack; F J Snoek Journal: Diabet Med Date: 2013-02 Impact factor: 4.359
Authors: Gregory P Forlenza; Zoey Li; Bruce A Buckingham; Jordan E Pinsker; Eda Cengiz; R Paul Wadwa; Laya Ekhlaspour; Mei Mei Church; Stuart A Weinzimer; Emily Jost; Tatiana Marcal; Camille Andre; Lori Carria; Vance Swanson; John W Lum; Craig Kollman; William Woodall; Roy W Beck Journal: Diabetes Care Date: 2018-08-08 Impact factor: 19.112
Authors: Melissa J Schoelwer; Jessica L Robic; Thibault Gautier; Chiara Fabris; Kelly Carr; Mary Clancy-Oliveri; Sue A Brown; Stacey M Anderson; Mark D DeBoer; Daniel R Cherñavvsky; Marc D Breton Journal: Diabetes Technol Ther Date: 2020-03-02 Impact factor: 6.118
Authors: Karishma A Datye; Daniel R Tilden; Angelee M Parmar; Eveline R Goethals; Sarah S Jaser Journal: Curr Diab Rep Date: 2021-05-15 Impact factor: 4.810
Authors: Yogish C Kudva; Lori M Laffel; Sue A Brown; Dan Raghinaru; Jordan E Pinsker; Laya Ekhlaspour; Carol J Levy; Laurel H Messer; Boris P Kovatchev; John W Lum; Roy W Beck; Linda Gonder-Frederick Journal: Diabetes Technol Ther Date: 2021-10 Impact factor: 7.337
Authors: Eleonora M Aiello; Sunil Deshpande; Basak Ozaslan; Kelilah L Wolkowicz; Eyal Dassau; Jordan E Pinsker; Francis J Doyle Journal: Curr Opin Biomed Eng Date: 2021-06-18